IDT Australia (ASX:IDT) has announced that the TGA has expanded the licensing conditions covering its Aseptic Sterile Processing (ASP) facility.
The updated license enables IDT to manufacture and supply Good Manufacturing Practice (GMP) injectable drugs for use in clinical trials in Australia and overseas.
This upgraded license allows the company to expand its offering to the clinical trial industry to include injectable medicines. IDT is already licensed to produce GMP Specialised Orals and Active Pharmaceutical Ingredients (APIs).
IDT CEO Paul McDonald said, “The upgraded licence will enable us to play a crucial role in supporting Australia’s sovereign manufacturing capabilities and the translation of research to address unmet medical needs. “We have the opportunity to become the ‘go to’ partner for clinical trials and expect to attract international pharmaceutical companies and researchers to undertake trials on Australian soil, which will contribute enormously to the growth of the Australian biotech industry.”